Analyst tracks

Andrew Fein, who joined H.C. Wainwright as a senior biotechnology analyst and managing director in May, initiated coverage of several companies, including cardiovascular company United Therapeutics Corp. (NASDAQ:UTHR), infectious disease play Synthetic Biologics Inc. (NYSE-M:SYN) and HCV and cystic fibrosis company Vertex Pharmaceuticals Inc.